GMP Biotinylated Human DLL4 Protein, His,Avitag™

Catalog # GMP-DL4H23

Product Details

DLL4 (Delta-like ligand 4) is a Notch ligand primarily expressed in vascular endothelium and thymic epithelial cells. In iPSC differentiation toward T and NK cells, DLL4 plays a pivotal role in directing hematopoietic progenitors toward the lymphoid lineage by activating Notch signaling. Through sustained Notch pathway engagement, DLL4 drives T-lineage commitment, supports thymic progenitor expansion, and promotes functional maturation of both T cells and NK cells, making it essential for generating immune effector cells from pluripotent stem cells.

Product Features and Advantages

- **Unique Clinical-Grade Offering**: The only GMP-grade DLL4 available, validated in multiple clinical trials and cell manufacturing processes.
- **Feeder-Free Culture Support**: Enables feeder cell-independent culture systems, streamlining T/NK cell production workflows.
- **Functional Differentiation Driver**: Specifically supports efficient and directed differentiation toward T and NK cell lineages.
- **Scalable and Reproducible**: Features stringent quality control and high lot-to-lot consistency for seamless transition from research to clinical manufacturing.

GMP Platform Advantages

- **Quality Assurance**: Global QMS with comprehensive and stringent QC release criteria.
- **End-to-End GMP Compliance**: Full manufacturing and QC under a cGMP system.
- **Comprehensive Control of Adventitious Agents**: Stringent biosafety from cell banks to final release.
- **Comprehensive Regulatory Support**: Includes RSF and DMF to meet global requirements.
- **Resilient Supply Chain**: Intelligent modular facilities ensure a stable global supply.
- **Professional Support**: Extensive manufacturing and application expertise to accelerate development.

Source

GMP Biotinylated Human DLL4 Protein, His,Avitag (GMP-DL4H23) is expressed from human 293 cells (HEK293). It contains AA Ser 27 - Pro 524 (Accession # NP_061947.1).

Molecular Characterization



This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™).

The protein has a calculated MW of 57.9 kDa. The protein migrates as 61 kDa±3 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

N-terminal Sequence Analysis

Ser-Gly-Val-Phe-Gln-Leu-Gln-Leu-Gln-Glu-Phe-Ile-Asn-Glu-Arg
(Routinely tested)

Labeling

Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

Biotinylation

As determined by Quantitative ELISA binding assay against streptavidin.

Endotoxin

Less than 10 EU/mg, tested by the LAL method in compliance with USP <85> and Ph. Eur. 2.6.14.

Host Cell Protein

<0.5 ng/μg of protein tested by ELISA.

Host Cell DNA

<0.02 ng/μg of protein tested by qPCR.

Sterility

Sterility testing was performed using the membrane filtration method in compliance with USP <71> and Ph. Eur. 2.6.1.

Mycoplasma

Negative

Purity

>95% as determined by SDS-PAGE.

Formulation

Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with protectants.

Contact us for customized product form or formulation.

Vial Specification

6R (20 mm neck finish)

Shipping

This product is supplied and shipped with blue ice, please inquire the shipping cost.

Storage

Upon receipt, store it immediately at -20°C or lower for long term storage.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

- -20°C to -70°C for 5 years in lyophilized state;
- -70°C for 12 months under sterile conditions after reconstitution.

ACRO Quality Management System

- QMS(ISO, GMP)
- Quality Advantages
- Quality Control Process

SDS-PAGE



GMP Biotinylated Human DLL4 Protein, His,Avitag on SDS-PAGE under reducing (R) and non-reducing (NR) conditions. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.

Bioactivity-SPR



GMP Biotinylated Human DLL4 Protein, His,Avitag (Cat. No. GMP-DL4H23) immobilized on CM5 Chip can bind Human NOTCH1 Protein, Fc Tag (Cat. No. NO1-H5255) with an affinity constant between 1.00 nM - 30.0 nM as determined in a SPR assay (Biacore 8K) (QC tested).

Application Data



CD34+ CD45+ hematopoietic cells were seeded on GMP Biotinylated Human DLL4 Protein, His,Avitag (Cat. No. GMP-DL4H23) coated plates and differentiated for 14 days, then flow cytometry was used to detect the expression of T-cell progenitor markers, CD7 and CD5. The GMP Biotinylated Human DLL4 Protein, His,Avitag together with SCF, TPO, Flt3L and IL7, could induce the formation of CD7+ and CD7+ CD5+ T-cell progenitors (Routinely tested).

Bioactivity-Stability



SPR assay demonstrates that the reconstituted GMP Biotinylated Human DLL4 Protein, His,Avitag (Cat. No. GMP-DL4H23) is stable at 37℃ for 24 hours.



SPR assay demonstrates that the reconstituted GMP Biotinylated Human DLL4 Protein, His,Avitag (Cat. No. GMP-DL4H23) is stable at 4℃ for 180 days.



SPR assay demonstrates that the reconstituted GMP Biotinylated Human DLL4 Protein, His,Avitag (Cat. No. GMP-DL4H23) is stable after 3 freeze-thaw cycles.

Background

Delta-like protein 4 (DLL4) is also known as Drosophila Delta homolog 4 (Delta4), which contains one DSL domain and eight EGF-like domains. DLL4 is expressed in vascular endothelium. DLL4 is involved in the Notch signaling pathway as Notch ligand, which can activates NOTCH1 and NOTCH4. DLL4 is involved in angiogenesis and negatively regulates endothelial cell proliferation and migration and angiogenic sprouting. DLL4 can bind to Notch-1 and Notch-4.

MANUFACTURING SPECIFICATIONS

ACROBiosystems GMP grade products are produced under a quality management system and in compliance with relevant guidelines: Ph. Eur General Chapter 5.2.12 Raw materials of biological origin for the production of cell-based and gene therapy medicinal products; USP<92>Growth Factors and Cytokines Used in Cell Therapy Manufacturing; USP<1043>Ancillary Materials for Cell, Gene, and Tissue-Engineered Products; ISO/TS 20399-1:2018, Biotechnology - Ancillary Materials Present During the Production of Cellular Therapeutic Products.

ACROBiosystems Quality Management System Contents：

- GMP-certified facility (compliance with FDA cGMP, EMA GMP, ICH, ISO9001/13485/MDSAP, and certified by third-party SGS, UL, and RX360)
- Animal origin-free materials, equipments, and facilities
- Materials sourced only from approved suppliers
- ISO 5 cleanrooms and automatic filling equipment
- Professional quality personnel and training programs
- Validated analytical testing methods in accordance with the ICH guidelines
- Safety Testing (Sterility, Mycoplasma, etc): compliant with USP, EP, etc
- In-depth stability studies
- Fully batch production and control records
- Equipment maintenance and calibration

ACROBiosystems provide rigorous quality control tests (fully validated equipment, processes and test methods) on our GMP grade products to ensure that they meet stringent standards in terms of purity, safety, activity and inter-batch stability, and each bulk QC lot mainly contains the following specific information:

- SDS-PAGE
- Protein content
- Endotoxin level
- Residual Host Cell DNA content
- Residual Host Cell Protein content
- Biological activity analysis
- Microbial testing
- Mycoplasma testing
- In vitro virus assay
- Residual moisture
- Batch-to-batch consistency

ACROBIOSYSTEMS - LEGAL NOTICES FOR GMP GRADE PRODUCTS

1. PRODUCT USE RESTRICTIONS & PROHIBITIONS

1.1 ACROBiosystems ("ACRO") GMP grade products ("Products") are designed for research, manufacturing use or ex vivo use.

1.2 Products are NOT intended for diagnostic purposes or for direct or indirect administration into humans.

1.3 Purchaser shall not market, distribute, or resell Products obtained from ACRO without ACRO's prior written consent.

2. REVERSE ENGINEERING PROHIBITED & CONFIDENTIALITY

2.1 Purchaser shall not reverse-engineer, decompile, disassemble, sequence, analyze via bioinformatics, or otherwise attempt to discover the structure, sequence, composition, construction, manufacturing process, or any trade secret embodied in the Products. Purchaser shall not permit any third party to undertake such activities.

2.2 All specifications, data, and know-how related to the Products provided by ACRO are ACRO's confidential information and shall be protected accordingly.

3. LIMITED WARRANTY & DISCLAIMERS

3.1 ACRO warrants solely that Products will conform to their published specifications when used under normal, specified laboratory/manufacturing conditions and within their labeled expiration date. THIS IS THE ONLY WARRANTY PROVIDED.

3.2 Purchaser assumes ALL risk and responsibility for:
(a) Determining the suitability of Products for Purchaser's intended application(s).
(b) Obtaining any necessary regulatory approvals or intellectual property licenses for Purchaser's use.
(c) Compliance with all applicable laws, regulations (including but not limited to cGMP/GLP where claimed), and industry standards.
(d) Conducting all necessary quality control, safety, efficacy, and validation testing of Products within Purchaser's process or final product.
(e) Proper storage, handling, and use of Products according to ACRO's instructions.

3.3 ACRO EXPRESSLY DISCLAIMS ALL OTHER WARRANTIES, WHETHER EXPRESS, IMPLIED, STATUTORY, OR OTHERWISE, INCLUDING BUT NOT LIMITED TO: (A) WARRANTIES OF MERCHANTABILITY; (B) WARRANTIES OF FITNESS FOR A PARTICULAR PURPOSE; (C) WARRANTIES OF NON-INFRINGEMENT; AND (D) WARRANTIES ARISING FROM COURSE OF DEALING OR USAGE OF TRADE.

4. LIMITATION OF LIABILITY

IN NO EVENT SHALL ACRO, ITS AFFILIATES, OR SUPPLIERS BE LIABLE FOR ANY OF THE FOLLOWING, HOWSOEVER ARISING (WHETHER IN CONTRACT, TORT (INCLUDING NEGLIGENCE), STRICT LIABILITY, STATUTE, OR OTHERWISE):
(a) LOST PROFITS, LOST REVENUE, LOST SAVINGS, LOSS OF USE, LOSS OF DATA, BUSINESS INTERRUPTION, OR ANY OTHER INDIRECT, INCIDENTAL, SPECIAL, PUNITIVE, OR CONSEQUENTIAL DAMAGES.
(b) ANY DIRECT DAMAGES, COSTS, OR EXPENSES EXCEEDING THE AMOUNT PAID BY PURCHASER FOR THE SPECIFIC PRODUCT(S) GIVING RISE TO THE CLAIM.
(c) DAMAGES ARISING FROM: (i) MISUSE, ABUSE, OR UNAUTHORIZED MODIFICATION OF PRODUCTS; (ii) USE BEYOND THE EXPIRATION DATE; (iii) IMPROPER STORAGE OR HANDLING; (iv) ACCIDENTAL DAMAGE; (v) FAILURE TO CONDUCT ADEQUATE VALIDATION OR TESTING BY PURCHASER; (vi) INFRINGEMENT CLAIMS RELATED TO PURCHASER'S USE; OR (vii) THE COST OF PROCURING SUBSTITUTE GOODS OR SERVICES.
(d) ANY PERSONAL INJURY, DEATH, OR DAMAGE TO TANGIBLE PROPERTY TO THE EXTENT PERMITTED BY LAW.

5. END USER ACKNOWLEDGEMENT & COMPLIANCE

5.1 By accepting, opening, or using the Products, the End User (Purchaser or its downstream recipient) agrees to be irrevocably bound by all terms herein.

5.2 End User explicitly acknowledges the Products are NOT FOR HUMAN ADMINISTRATION and agrees not to use them in any in vivo human application, directly or indirectly.

5.3 End Users unwilling to accept these terms must immediately: (a) cease all use; (b) notify ACRO or their supplier; and (c) return the unopened, unused Products.

5.4 ACRO reserves the right to audit End User's compliance with these restrictions upon reasonable notice.

ACRO has the right, at its sole discretion, to modify, add or remove any terms herein without notice to Purchaser and/or End User. Any changes to these terms are effective immediately following the updating of such changes on ACRO’s website or published specifications or product-related documents.